Uptake of costly therapies, Imbruvica and Revlimid, will offset generic and biosimilar sales erosion of the wider MCL market.
By Gunel Huseynova, Analyst
24 April 2016
I joined Datamonitor Healthcare as an Analyst in November 2015, having completed a PhD in Genetics at the University of ...
Read full bio
The increased uptake of more expensive therapies over the forecast period will compensate for the loss of sales due to generic/biosimilar market entry. All marketed drugs except Imbruvica will lose market shares to biosimilars and generics during the 2016–25 forecast period. Market exclusivity and patents covering Rituxan (rituximab; Biogen/Roche/Chugai/Zenyaku Kogyo), Revlimid, Velcade (bortezomib; Takeda/Johnson & Johnson), and Torisel (temsirolimus; Pfizer) will expire during the forecast period, leading to loss of market share to biosimilars and generics. However, Datamonitor Healthcare anticipates that the increased uptake and potential first-line label expansion of Imbruvica, and Revlimid’s expected EU approval, will offset generic and biosimilar erosion during the forecast period.
Mantle cell lymphoma market value across the US, Japan, and five major EU markets ($m), 2016–25
Source: Datamonitor Healthcare
This is excerpted from Datamonitor Healthcare’s Mantle Cell Lymphoma: Forecast, exploring the impact of patent expiration, label expansion and new approvals of key branded drugs on the mantle cell lymphoma market during 2016–25.
Get your free demo today – simply fill out the form to the right.